Literature DB >> 10767715

Identification of frequent chromosomal aberrations in ductal adenocarcinoma of the pancreas by comparative genomic hybridization (CGH).

C Schleger1, N Arens, H Zentgraf, U Bleyl, C Verbeke.   

Abstract

Despite the continuous progress in molecular methodology, the genetic events involved in the initiation and progression of ductal adenocarcinoma of the pancreas remain largely unknown. In this study, 33 pancreatic ductal adenocarcinomas were screened for genomic alterations by comparative genomic hybridization (CGH). To date, most CGH studies of pancreatic cancer have been based on cell lines. To emphasize genetic imbalances that are involved in the in vivo development and progression of pancreatic carcinoma only fresh-frozen or paraffin-embedded tumour samples were analysed in the present study. Twenty-two tumours (67%) showed genomic alterations involving up to three (12%) or more (55%) chromosomal regions. The number and nature of the genetic imbalances did not, however, correlate with tumour stage or grade. Chromosome 18 was preferentially altered in the tumours analysed. Frequent chromosomal losses were found at 18q, 10q, 8p, and 13q. Commonly gained regions were located on 8q and 3q. Moreover, high copy number amplifications of the chromosomal regions 5p, 8q22-ter, 12p12-cen, 19q12-13.2, and 20q were identified. These data provide evidence for the occurrence of characteristic genomic alterations which are of biological relevance for the genesis of pancreatic cancer. The identified altered chromosomal regions may harbour tumour genes which involved in the multistep process of pancreatic carcinogenesis. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10767715     DOI: 10.1002/(SICI)1096-9896(200005)191:1<27::AID-PATH582>3.0.CO;2-J

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  20 in total

1.  Genetics and pathology of pancreatic cancer.

Authors:  Jordan M Winter; Anirban Maitra; Charles J Yeo
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

Review 2.  Genomics of pancreatic cancer: does it make any improvement in diagnosis, prognosis and therapy?

Authors:  László Kopper; Attila Zalatnai; József Tímár
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

3.  Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Marco Dal Molin; Seung-Mo Hong; Sachidanand Hebbar; Rajni Sharma; Francesca Scrimieri; Roeland F de Wilde; Skye C Mayo; Michael Goggins; Christopher L Wolfgang; Richard D Schulick; Ming-Tseh Lin; James R Eshleman; Ralph H Hruban; Anirban Maitra; Hanno Matthaei
Journal:  Hum Pathol       Date:  2011-09-21       Impact factor: 3.466

Review 4.  The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.

Authors:  Nardin Samuel; Thomas J Hudson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-12-20       Impact factor: 46.802

5.  Synchronous primary epithelial tumors of the pancreas.

Authors:  Nikolaos P Karidis; Panoraia Paraskeva; Dimitrios Mantas
Journal:  Int J Surg Case Rep       Date:  2012-05-25

6.  Intraductal papillary-mucinous neoplasia of the pancreas: Histopathology and molecular biology.

Authors:  Caroline S Verbeke
Journal:  World J Gastrointest Surg       Date:  2010-10-27

7.  Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases.

Authors:  Frank Bergmann; Sebastian Aulmann; Bence Sipos; Matthias Kloor; Anja von Heydebreck; Johannes Schweipert; Andreas Harjung; Philipp Mayer; Werner Hartwig; Gerhard Moldenhauer; David Capper; Gerhard Dyckhoff; Kolja Freier; Esther Herpel; Anja Schleider; Peter Schirmacher; Gunhild Mechtersheimer; Günter Klöppel; Hendrik Bläker
Journal:  Virchows Arch       Date:  2014-10-09       Impact factor: 4.064

8.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

9.  Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group.

Authors:  Ralf Hildenbrand; Marco Niedergethmann; Alexander Marx; Djeda Belharazem; Heike Allgayer; Christiane Schleger; Philipp Ströbel
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

10.  The reg4 gene, amplified in the early stages of pancreatic cancer development, is a promising therapeutic target.

Authors:  Aude Legoffic; Ezequiel Calvo; Carla Cano; Emma Folch-Puy; Marc Barthet; Jean Robert Delpero; Montse Ferrés-Masó; Jean Charles Dagorn; Daniel Closa; Juan Iovanna
Journal:  PLoS One       Date:  2009-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.